| SEC For | m 4 | | | | | | | | | | | | | | | | | | |
|--|---|--|--|----------------------------|--|--|--------|---|-----------------|---------------------|--|--------------------------------------|---|--|-----------|--|--|--|--|
| | FORM | 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | | | | | | OMB APPROVAL | | | |
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | | | | | ursuan | t to Sectio | n 16(| a) of the Secu | urities Ex | | HIP | OMB N Estima | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | | | | | |
| 1. Name and Address of Reporting Person [*] Kaye Edward M. MD | | | | | 2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK] | | | | | | | | ck all applica | able) | 10% Owner | | | | |
| (Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/15/2022 | | | | | | | | Officer (below) | give title | CEO | | | | |
| 45 WIGGINS AVENUE (Street) BEDFORD MA 01730 | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/L | | | | ransacti e | action 2A. Deemed Execution Dat | | | 3. Transacti Code (Ins | 4. S | | | ed (A) or | 5. Amoun Securities Beneficia Owned Fo | Form Ily (D) o | | Direct Ir Indirect B str. 4) C | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | Code V | V Amou | | (A) or (D) Price | | Reported Transacti (Instr. 3 a | on(s) | | | (Instr. 4) | | | |
| | | | Table II - Dei (e.ç | | | | | luired, Dis s, options | | | | | Owned | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exer Expiration D (Month/Day/ | ate | und | 7. Title an of Securit Underlyin Derivative (Instr. 3 ar | ies g Security | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expirat Date | tion | Title | Amount or Number of Shares | | (Instr. 4) | | | | | |
| Employee Stock Option (Right to Buy) | \$20.34 | 03/15/2022 | | А | | 308,000 | | (1) | 03/14/2 | 2032 | Common Stock | 308,000 | ,000 \$0.00 | | 308,000 | | | | |

Explanation of Responses:

1. The option vests as to 1/48th of the total shares on April 15, 2022 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

<u>/s/ Stephen Tulipano, Attorney-</u> <u>in-Fact</u> 03/17/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.